Agios
Agios is a commercial-stage biopharmaceutical company pioneering therapies for rare diseases through its leadership in cellular metabolism science. Its first FDA-approved therapy treats hemolytic anemia in adults with pyruvate kinase deficiency, and its lead pipeline candidate mitapivat is in late-stage trials for thalassemia and sickle cell disease. Agios also advances novel PK activators and multiple preclinical programs targeting rare hematologic conditions.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountJul 2013
Nov 2011
Apr 2010
Jul 2008
Create a free account to see which investors have funded this company.
Create Free Account
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Health insurance company using technology to make health care simple, affordable, and accessible.
